Pleural Irrigation With Normal Saline Versus Intrapleural Fibrinolytic
NCT05903417 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40
Last updated 2026-02-24
Summary
Parapneumonic effusions caused by an infection of the pleural membranes occur in 40-57% of cases of pneumonia. A variable percentage (10-20%) of parapneumonic effusions progresses to empyema (pus) and/or abscess formation (encapsulation). Pleural infection is associated with significant morbidity and mortality which may be as high as 20-35% in immunocompromised patients Standard treatment of these collections in adults involves antibiotic therapy, effective drainage of infected fluid and surgical intervention if conservative management fails. For parapneumonic effusions which require clearance, appropriate therapy is effective drainage via an intercostal catheter (ICC) with antibiotic therapy. The presence of fibrinous septae in the pleural space, known as loculations, may result in inadequate drainage of effusions and therefore non-resolution of infection and systemic sepsis. Without effective intercostal catheter drainage, surgical intervention (VATS or open) has usually been required to clear loculations for resolution of infection.
Non-surgical treatment options to reduce the impact of adhesions and locule include (in addition to appropriate antibiotic therapy) single and multiple thoracocentesis, or single and multiple intercostal tube thoracostomies, with or without intrapleural fibrinolytic agents.
Fibrinolytic agents including streptokinase, urokinase, alteplase and recombinant tissue plasminogen activator (rTPA) have been used safely and effectively intrapleurally for complicated pleural effusion and empyema.
MIST 2 trial has established intrapleural therapy as the mainstay of CPEE treatment hence avoiding surgery and decreasing the length of hospitalization; however, little is known about the correct dosage needed for tPA and DNase. Dose and duration of intrapleural therapy based on MIST 2 involve multiple dosing and can be time-consuming for health care providers . Previous studies showed that complexity of treatment is a factor associated with poor adherence to a regimen. For this reason, trying to find the minimum effective dose and simplifying the regimen is essential for minimizing side effects and maximizing adherence. The review of currently available literature shows concurrent administration of tPA and DNase to be safe and effective even at lower cumulative dose Other study was carried out in May 2022 in which Modified regimen intrapleural alteplase 16 mg t-PA with 5 mg DNase for total 3 doses that administered sequentially within 24 h had been used. In this study, modified regimen of t-PA and DNase offer an alternative therapeutic option for patients that are unfit or refuse surgical intervention but persistent pleural infection. They have demonstrated similar treatment success comparable to other studies, as evidenced by improvement on pleural fluid drainage and reduction in pleural opacity on day 7 chest x-ray was approximately 50% from the baseline using intrapleural 16 mg t-PA with 5 mg DNase. The mechanism of action of t-PA and DNase in pleural cavity remain unclear. Studies suggested that IPFT may trigger the monocyte chemoattractant protein 1 (MCP-1) pathway which promote pleural fluid formation and subsequently causes a therapeutic lavage effect that increases pleural fluid drainage.
Another option for intrapleural therapy may be pleural irrigation with normal saline. The idea behind is to dilute and remove bacteria, cytokines, inflammatory cells, and pro-fibrinogenic coagulation factors, which induce pleural fluid organization. Also, the mechanical process of irrigation increases pleural fluid drainage by reducing stasis and organization of the intrapleural contents .
A randomised controlled pilot study in which saline pleural irrigation (three times per day for 3 days) plus best-practice management was compared with best-practice management alone was performed in patients with pleural infection requiring chest-tube drainage. The primary outcome was percentage change in computed tomography pleural fluid volume from day 0 to day 3. Patients receiving saline irrigation had a significantly greater reduction in pleural collection volume on computed tomography compared to those receiving standard care. Significantly fewer patients in the irrigation group were referred for surgery (30).
However, till date there is no study done on head to head comparison between intrapleural fibrinolytic with alteplase and DNAse Versus Pleural irrigationwith normal saline.
Conditions
- Pleural Infection
Interventions
- DRUG
-
Intrapleural fibrinolytic with alteplase 5mg and pulmozyme 5 mg
The number of installation of intrapleural t-PA/DNase depends on the discretion of the treating physician (at least 6 hours apart between each dose). 5mg of Alteplase (t-PA) and 5mg DNase are diluted in each 50ml of 0.9% sodium chloride solution. t-PA and DNase are not mixed together in one syringe. In brief , both medication are administered sequentially which t-PA is first instilled intrapleurally and the chest tube is then clamped for 45 minutes, then unclamped to allow free drainage for 45 minutes. The same procedure is then repeated for DNase. Selection of the timing of treatment and removal of chest tube are depending on the chest physician's judgement.
- OTHER
-
Saline irrigation with 250 mls normal saline (over 1 hour)
subjects were administered 250 ml of 0.9% sodium chloride via chest tube a three way tap from a drip stand which were allowed drainage freely over 1 hour. Pleural irrigation will be performed minimum of 3 installations and maximum of 9 installation (3 times per day).
Sponsors & Collaborators
-
National University of Malaysia
lead OTHER
Principal Investigators
-
Mohamed Faisal Abdul Hamid, MBBS (IIUM) · National University of Malaysia
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2023-07-10
- Primary Completion
- 2025-10-14
- Completion
- 2025-10-14
Countries
- Malaysia
Study Locations
More Related Trials
-
Alteplase Through an Indwelling Pleural Catheter for the Management of Symptomatic Septated Malignant Pleural Effusion
NCT06184321 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Fibrinolysis Compared to Thoracoscopy for Pleural Infection
NCT03468933 ·Status: COMPLETED ·Phase: PHASE4
-
Management of Malignant Pleural Effusion With Indwelling Pleural Catheter Versus Silver Nitrate Pleurodesis
NCT03781908 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Efficacy and Safety of Activase (Ateplase) vs Placebo in Complicated Pleural Effusions (CPE)/Empyemas
NCT00468104 ·Status: COMPLETED ·Phase: NA
-
Intrapleural Fibrinolytic Therapy to Enhance Chemical Pleurodesis Enhance Chemical Pleurodesis
NCT04806373 ·Status: COMPLETED ·Phase: PHASE4
-
Trial of Reduced Alteplase Dose for Parapneumonic Effusion (TRAPPE)
NCT05766124 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
Fibrinolysis Compared to Thoracoscopy for Pleural Infection
NCT02973139 ·Status: COMPLETED ·Phase: NA
-
Evaluating Different Modalities for Pleural Adhesiolysis at Assuit University Hospital
NCT03172052 ·Status: UNKNOWN ·Phase: PHASE4
-
Trial of Antiseptic Irrigation for Pleural Infection
NCT05546762 ·Status: UNKNOWN ·Phase: PHASE2
-
A Prospective, Randomized Controlled Trial for a Rapid Pleurodesis Protocol for the Management of Pleural Effusions
NCT00758316 ·Status: COMPLETED ·Phase: PHASE3
-
Once Daily Intrapleural Enzyme Therapy in Complicated Parapneumonic Effusion or Empyema
NCT07095361 ·Status: RECRUITING ·Phase: PHASE4
-
Multicentre Study Comparing Indwelling Pleural Catheter With Talc Pleurodesis for Malignant Pleural Effusion Management
NCT02045121 ·Status: UNKNOWN ·Phase: NA
-
Alteplase for Treatment of Empyema and Complicated Parapneumonic Effusion
NCT00103766 ·Status: UNKNOWN ·Phase: NA
-
Antiseptic Irrigation for Pleural Infection
NCT04761133 ·Status: COMPLETED ·Phase: PHASE1
-
Rapid Pleurodesis Through an Indwelling Pleural Catheter
NCT03325192 ·Status: TERMINATED ·Phase: NA
-
Management of Pleural Space Infections
NCT03873766 ·Status: COMPLETED ·Phase: PHASE4
-
Ultrasound-guided Pigtail Catheter Versus Intercostal Tube Drainage of Non-traumatic Exudative Pleural Effusion
NCT06099054 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Efficacy of Fibrinolytic Agents in Complicated Pleural Effusion
NCT03716375 ·Status: UNKNOWN ·Phase: NA
-
Out Patient Talc Slurry Via Indwelling Pleural Catheter for Malignant Pleural Effusion Vs Usual Inpatient Management
NCT02517749 ·Status: COMPLETED ·Phase: NA
-
Intrapleural Minocycline Following Simple Aspiration for Primary Spontaneous Pneumothorax
NCT00520221 ·Status: COMPLETED
-
Diagnostic Yield of Agitated Exudative Non-infected Pleural Effusion
NCT05819294 ·Status: UNKNOWN ·Phase: NA
-
The Safety and Efficacy of Fibrinolysis in Patients With an Indwelling Pleural Catheter for Multi-loculated Malignant Pleural Effusion.
NCT03678090 ·Status: WITHDRAWN ·Phase: PHASE2
-
Thoracoscopic Pleural Lavage and Brushing in Undiagnosed Pleural Effusion
NCT06066398 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Fluid Agitation Microbiologic Yield In Pleural Infection Feasibility Study
NCT05702580 ·Status: COMPLETED ·Phase: NA
-
Treatment of Complicated Parapneumonic Effusion With Fibrinolytic Therapy Versus VATs Decortication
NCT03583931 ·Status: COMPLETED ·Phase: NA